Linzagolix will only be available for patients whose previous medical or surgical treatments have been unsuccessful.

A new at-home pill for endometriosis has been approved for use on the NHS.The once-a-day tablet, called linzagolix but also ...

A new daily tablet for endometriosis, called linzagolix (also known as Yselty), has been approved for use on the NHS and is ...

Pfizer and Myovant have begun a late-stage trial of their potential uterine fibroid drug relugolix, as part of a contraceptive combination tablet. The FDA is already reviewing data from two ...

Linzagolix (Yselty) with hormonal add-back therapy will offer a new at-home treatment option for some women in England with ...

Myovant has chalked up a second approval for its flagship drug relugolix from the FDA, becoming the first once-daily oral drug in the US to treat heavy menstrual bleeding associated with uterine ...

The pill, known as relugolix–estradiol–norethisterone (or relugolix combination therapy, branded as Ryeqo), is considered a breakthrough for the 1.5 million people in the UK living with ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

The treatment, known as relugolix combination therapy or Ryeqo, is expected to be issued to 1,000 women a year. Endometriosis affects around 1.5 million women in the UK. Often wrongly dubbed as ...

Relugolix–estradiol–norethisterone (relugolix combination therapy [CT]) can be used, within its marketing authorisation, as an option for treating symptoms of endometriosis in adults of reproductive ...

In March, the National Institute for Health and Care Excellence (NICE) approved a similar treatment called relugolix combination therapy. The two pills differ slightly as linzagolix will require ...